Gene Associated With Spread of Prostate Cancer Identified

OncologyONCOLOGY Vol 11 No 2
Volume 11
Issue 2

Researchers at Columbia-Presbyterian Medical Center have identified a gene that may control the metastatic spread of prostate cancer and tumor growth. If confirmed, the preliminary findings may eventually help doctors identify patients whose

Researchers at Columbia-Presbyterian Medical Center have identifieda gene that may control the metastatic spread of prostate cancer and tumorgrowth. If confirmed, the preliminary findings may eventually help doctorsidentify patients whose prostate cancer is likely to spread and facilitatemore effective treatment of the disease.

"Currently, there is no way to predict the aggressiveness of prostatecancer," says Dr. Paul B. Fisher, professor of clinical pathology,director of neuro-oncology research, and the Chernow Research Scientistin pathology and urology at Columbia University College of Physicians &Surgeons. "If additional research proves that this gene is associatedonly with aggressive prostate cancer, we will have a better understandingof how to treat patients."

Dr. Fisher and his team found the gene, known as prostate carcinomatumor antigen-1 (PCTA-1), on the surface of human prostate cancer cellsfrom patients with advanced disease but not on the surface of cells fromnormal prostates or from the glands of those with benign prostate disease.

The study, published in the Proceedings of the National Academy ofSciences, reports that PCTA-1 produces a protein known to allow cancercells to attach both to one another and to distant sites in the body. Bothprocesses are considered essential for a tumor to metastasize.

The researchers used monoclonal antibodies developed by a patent-pendingtechnique known as surface epitope/masking to identify PCTA-1. Dr. Fisherbelieves that the antibodies could rapidly be used therapeutically. Whenthe monoclonal antibodies are used to treat mice bearing human prostatecancer, they slow the growth of the cancer and disease progression, possiblyby blocking the site on the surface of cancer cells that allows them togrow.

Additional research must be done to clarify the role of PTCA-1 in prostatecancer. Experiments will begin soon in Dr. Fisher's laboratory to testthe effect of blocking PCTA-1 expression on cancer development.

Related Videos
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Financial constraints and a lack of education among some patients and providers must be addressed to improve the real-world use of certain prostate cancer therapies, says Neeraj Agarwal, MD.
Novel anti-PSMA monoclonal antibody rosopatamab is capable of carrying a bigger payload of radiation particles, which may potentially reduce doses for patients with prostate cancer, says Neeraj Agarwal, MD.
Findings from recent studies support the use of artificial intelligence-based tools in the context of radiation therapy for patients with localized prostate cancer, according to Neeraj Agarwal, MD.
Germline testing may elucidate important mutations in patients with metastatic prostate cancer who may be eligible to receive treatment with PARP inhibitors, according to Neeraj Agarwal, MD.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Artificial intelligence programs may help introduce new care strategies that minimize the risk of adverse effects in patients with prostate cancer, according to Wayne G. Brisbane, MD.
An artificial intelligence algorithm appears to create accurate focal treatment margins in patients with prostate cancer, according to Wayne G. Brisbane, MD.
Artificial intelligence may be useful in screening for prostate cancer in patients with elevated prostate specific antigen levels who have undergone MRI, according to Wayne G. Brisbane, MD.
Related Content